Navigation Links
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:9/24/2008

ts travel in the circulatory system to the brain and muscles causing the nerves to become over-stimulated which leads to massive convulsions and death in severe cases.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) -- a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) -- a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 With ... cytometry is experiencing a rise in active partnerships. ... in underdeveloped nations to quantitate CD4 cell markers ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... the Global Flow Cytometry Market ( http://www.frost.com/nf0e ), ...
(Date:8/31/2015)...  The departments of Drug and Alcohol Programs (DDAP) ... 90 to raise awareness for International Overdose Awareness Day ... Pennsylvania and help more Pennsylvanians with substance ... the Building Bridges to Recovery initiative. ... to a disease that is fully treatable, if given ...
(Date:8/31/2015)... Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest independent ... & CEO, and Sean Whelan , CFO, will present ... and Mr. Whelan are scheduled to participate in the Wells ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... participate in the Robert W. Baird 2015 Healthcare Conference in ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:9/1/2015)... ... 01, 2015 , ... The PracticeMatch Career Fair ... the Marriott Indianapolis Downtown, 350 West Maryland Street, Indianapolis, IN 46225. More than ... the country. All specialties will be represented. Attendees will enjoy free hors d’oeuvres ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® provides information on defining ... what to look for and expect when searching for resources, as well as ... Canoga Park, CA by CEO, Richard Weatherman and Co-Founder Piroska Zalkadi, AdvantagePlusCaregivers.com® grew ...
(Date:9/1/2015)... ... September 01, 2015 , ... The integration of Practice ... from Practice Perfect to FOTO enabling cost and time savings, reducing errors and ... Presement, President of Practice Perfect, stated "FOTO is a natural extension of Practice ...
(Date:9/1/2015)... ... 01, 2015 , ... Routines… every family has them. Whether it’s a morning ... for parents, caregivers and children too. Here are three reasons why routines can be ... more fluid. When a routine is implemented into a child’s schedule, they are able ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4
... if parent, sibling has the movement disorder, study shows , ... of people who have restless legs syndrome are also more ... , The authors of the study, which is published in ... the findings will raise awareness of the condition for both ...
... ... syndrome , ... 2010 -- One person can make a difference, one dollar at a time: that’s the ... center for people with Trisomy 21 (better known as Down syndrome). Launched one week ago ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... Sprint 4G, CradlePoint MBR1200 Router makes instant Internet access simple for small or remote ... , ... (PRWEB) May 10, 2010 -- Sprint (NYSE: S) has certified CradlePoint’s MBR1200 Failsafe Gigabit ...
... Rockville, Md., May 10, 2010 To promote ... labelsand to address the widespread problem of patient ... the U.S. Pharmacopeial Convention (USP) recently issued a ... on dispensed prescription packaging. The recommendations are patient-centered, ...
... monitored with measurement devices implanted inside a living body. ... aware of the presence of the implant. An example ... that has long since become standard treatment for heart ... of Technology (TUT) believes that the next tech-savvy generation ...
Cached Medicine News:Health News:Restless Legs Syndrome Can Have Family Ties 2Health News:Charity Asks for $1 2Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 3Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 4Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 5Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 6Health News:Panel recommends standardizing prescription container labeling 2Health News:Panel recommends standardizing prescription container labeling 3Health News:Panel recommends standardizing prescription container labeling 4Health News:Vital functions monitored with wearable and implantable devices 2Health News:Vital functions monitored with wearable and implantable devices 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: